Search Results

Biotech Beach

Kernel Launches Observational Study Using Flow2 Neuroimaging Technology to Identify Biomarkers of Depression Treatment Response

Kernel, an innovator in non-invasive neuroimaging technology, announces the first patient has been measured in an observational study of depression treatments using Kernel’s revolutionary Flow2 neuroimaging technology.

August 29, 2023

·

3 min read

Biotech Beach

Kernel Launches Cognitive Decline Study Using Flow2 Neuroimaging Technology

Kernel is excited to announce the commencement of an observational study focused on characterizing early cognitive decline.

August 21, 2023

·

3 min read

Biotech Beach

Kernel Introduces Flow2: Revolutionary Advanced Neuroimaging Technology Enabling Precision Neuromedicine

Kernel, a pioneer in neuroimaging technology, is proud to unveil its groundbreaking Flow2 system, a major leap forward in the field of functional neuroimaging.

July 31, 2023

·

2 min read

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Announces Promising Results from Sponsored Kernel Flow ® Feasibility Study Measuring Psychedelic Effects on the Brain.

January 18, 2023

·

9 min read

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Announces Initiation of Kernel Flow ® Feasibility Study Measuring Psychedelic Effects on the Brain.

March 31, 2022

·

7 min read

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin Inc. today announced that an Institutional Review Board (“IRB”) has approved a Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow.

January 11, 2022

·

5 min read

Pharm Country

Tweaking Corn Kernels with CRISPR

Corn — or maize — has changed over thousands of years from weedy plants that make ears with less than a dozen kernels to the cobs packed with hundreds of juicy kernels that we see on farms

February 22, 2021

·

2 min read

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Cybin Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the Company’s sponsored feasibility study using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.

October 26, 2021

·

6 min read

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure Ketamine’s psychedelic effect on cerebral cortex hemodynamics.

June 1, 2021

·

4 min read

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Kernel, based in Los Angeles, CA, was founded in 2016 and has raised US$104 million to date, including investment from founder Bryan Johnson, General Catalyst and Khosla Ventures.

January 11, 2021

·

8 min read